Tremendous talk by Dr. Kailey Oppat @winshipatemory.bsky.social on #FGFR and #IDH interaction with #immune signatures in #cholangiocarcinoma via collab w #carisls @cholangiocarcinoma.bsky.social annual meeting!
April 10, 2025 at 11:15 PM
Tremendous talk by Dr. Kailey Oppat @winshipatemory.bsky.social on #FGFR and #IDH interaction with #immune signatures in #cholangiocarcinoma via collab w #carisls @cholangiocarcinoma.bsky.social annual meeting!
Outstanding ASCO 2025- Caris POA Annual Meeting with excellent presentations and panel discussion. Congrats to the incoming POA Disease Group Chairs. @carisls @ASCO
May 30, 2025 at 12:00 AM
Outstanding ASCO 2025- Caris POA Annual Meeting with excellent presentations and panel discussion. Congrats to the incoming POA Disease Group Chairs. @carisls @ASCO
Good conversation at #GI26 with colleagues from @Bayer regarding opportunities in precision oncology and @WIN_Consortium @carisls @ccuris15
January 9, 2026 at 8:18 PM
Good conversation at #GI26 with colleagues from @Bayer regarding opportunities in precision oncology and @WIN_Consortium @carisls @ccuris15
Group photo of in person attendees this morning at the Inaugural National Caris Precision Oncology Alliance Member Meeting at @BrownUniversity @carisls
April 28, 2026 at 10:24 PM
Group photo of in person attendees this morning at the Inaugural National Caris Precision Oncology Alliance Member Meeting at @BrownUniversity @carisls
Looking forward to the inaugural regional @carisls @BrownUniversity Precision Oncology event tomorrow April 28, 2026 for New England in Providence, Rhode Island.
April 27, 2026 at 1:03 PM
Looking forward to the inaugural regional @carisls @BrownUniversity Precision Oncology event tomorrow April 28, 2026 for New England in Providence, Rhode Island.
Keynote and first session faculty (Flaherty @MassGenBrigham, Elton @ConcertAI, Spetzler @carisls, El-Deiry @BrownMedicine) at 2025 WIN symposium with Dr. Kaelin @DanaFarber.
@WIN_Consortium @Dr_R_Kurzrock @AdvPrecMed
@WIN_Consortium @Dr_R_Kurzrock @AdvPrecMed
October 4, 2025 at 8:55 AM
Keynote and first session faculty (Flaherty @MassGenBrigham, Elton @ConcertAI, Spetzler @carisls, El-Deiry @BrownMedicine) at 2025 WIN symposium with Dr. Kaelin @DanaFarber.
@WIN_Consortium @Dr_R_Kurzrock @AdvPrecMed
@WIN_Consortium @Dr_R_Kurzrock @AdvPrecMed
Sharing collaborative manuscript from the @carisls Precision Oncology Alliance
Molecular and immune landscape of tumours in geriatric patients with non-small cell lung cancer, melanoma and renal cell carcinoma
pubmed.ncbi.nlm.nih.gov/39885940/
Molecular and immune landscape of tumours in geriatric patients with non-small cell lung cancer, melanoma and renal cell carcinoma
pubmed.ncbi.nlm.nih.gov/39885940/
Molecular and immune landscape of tumours in geriatric patients with non-small cell lung cancer, melanoma and renal cell carcinoma - PubMed
Our findings reveal tumour type-specific expression profiles, TIMEs and response signatures to ICIs in patients ≥80, supporting further biomarker investigations in this population.
pubmed.ncbi.nlm.nih.gov
January 31, 2025 at 2:47 PM
Sharing collaborative manuscript from the @carisls Precision Oncology Alliance
Molecular and immune landscape of tumours in geriatric patients with non-small cell lung cancer, melanoma and renal cell carcinoma
pubmed.ncbi.nlm.nih.gov/39885940/
Molecular and immune landscape of tumours in geriatric patients with non-small cell lung cancer, melanoma and renal cell carcinoma
pubmed.ncbi.nlm.nih.gov/39885940/
Dr. Milan Radovich @carisls discusses annotated Caris dataset, the Caris Precision Oncology Alliance with 97 members, importance of RNA analysis for fusion detection, Quantum Report & Digital Path at 2025 @WIN_Consortium Symposium in collaboration with @AdvPrecMed @Dr_R_Kurzrock
October 5, 2025 at 6:59 PM
Dr. Milan Radovich @carisls discusses annotated Caris dataset, the Caris Precision Oncology Alliance with 97 members, importance of RNA analysis for fusion detection, Quantum Report & Digital Path at 2025 @WIN_Consortium Symposium in collaboration with @AdvPrecMed @Dr_R_Kurzrock
Excited to see publication @BrownMedicine @BrownUnivHealth from @BrownUniversity participation in @carisls Precision Oncology Alliance as member.
Large-Scale Multiomic Analysis Identifies Anatomic Differences and Immunogenic Potential in Subtypes of Leiomyosarcoma
aacrjournals.org/clincancerre...
Large-Scale Multiomic Analysis Identifies Anatomic Differences and Immunogenic Potential in Subtypes of Leiomyosarcoma
aacrjournals.org/clincancerre...
Large-Scale Multiomic Analysis Identifies Anatomic Differences and Immunogenic Potential in Subtypes of Leiomyosarcoma
AbstractPurpose:. Comprehensive molecular profiling was used to define the genomic and immune landscapes of leiomyosarcomas (LMS) by anatomic subtypes, which have not been completely characterized.Exp...
aacrjournals.org
May 1, 2025 at 5:40 PM
Excited to see publication @BrownMedicine @BrownUnivHealth from @BrownUniversity participation in @carisls Precision Oncology Alliance as member.
Large-Scale Multiomic Analysis Identifies Anatomic Differences and Immunogenic Potential in Subtypes of Leiomyosarcoma
aacrjournals.org/clincancerre...
Large-Scale Multiomic Analysis Identifies Anatomic Differences and Immunogenic Potential in Subtypes of Leiomyosarcoma
aacrjournals.org/clincancerre...
Collaborative MS Abraham et al colleagues @carisls. Caris Assure LB AI platform evaluates MRD, predicts recurrence.
Validation of AI-enabled exome/transcriptome liquid biopsy platform for early detection, MRD, disease monitoring, & therapy selection for solid tumors
pubmed.ncbi.nlm.nih.gov/40596693/
Validation of AI-enabled exome/transcriptome liquid biopsy platform for early detection, MRD, disease monitoring, & therapy selection for solid tumors
pubmed.ncbi.nlm.nih.gov/40596693/
Validation of an AI-enabled exome/transcriptome liquid biopsy platform for early detection, MRD, disease monitoring, and therapy selection for solid tumors - PubMed
Effective clinical management of patients with cancer requires highly accurate diagnosis, precise therapy selection, and highly sensitive monitoring of disease burden. Caris Assure is a multifunctiona...
pubmed.ncbi.nlm.nih.gov
July 2, 2025 at 2:10 PM
Collaborative MS Abraham et al colleagues @carisls. Caris Assure LB AI platform evaluates MRD, predicts recurrence.
Validation of AI-enabled exome/transcriptome liquid biopsy platform for early detection, MRD, disease monitoring, & therapy selection for solid tumors
pubmed.ncbi.nlm.nih.gov/40596693/
Validation of AI-enabled exome/transcriptome liquid biopsy platform for early detection, MRD, disease monitoring, & therapy selection for solid tumors
pubmed.ncbi.nlm.nih.gov/40596693/
Great to see this event come together at @BrownUniversity @carisls
April 10, 2026 at 4:14 PM
Great to see this event come together at @BrownUniversity @carisls
Outstanding panel of experts including Drs. Sholler @PennState, Zhang @WakeForest, Sayour @uflorida, Radovich @carisls, Wang @IcahnMountSinai & Kraveca @MedUnivSC assembled for presentations, discussion & collab in Peds Oncology at 2025 WIN Symposium in collaboration with @AdvPrecMed @Dr_R_Kurzrock
October 5, 2025 at 6:31 PM
Outstanding panel of experts including Drs. Sholler @PennState, Zhang @WakeForest, Sayour @uflorida, Radovich @carisls, Wang @IcahnMountSinai & Kraveca @MedUnivSC assembled for presentations, discussion & collab in Peds Oncology at 2025 WIN Symposium in collaboration with @AdvPrecMed @Dr_R_Kurzrock
Great to see Dr. Sewanti Limaye, Dr. Jake Scott @CancerConnector @ClevelandClinic, colleagues from @BrownMedicine, including Dr. Bene Carneiro @bcarneiro7, @SenduraiMani, @LiangChengMD, Matt Hadfield, Dr. @LiaTsimberidou from @MDAndersonNews, and Milan @carisls at 2025 WIN Symposium in Philly.
October 4, 2025 at 9:20 AM
Great to see Dr. Sewanti Limaye, Dr. Jake Scott @CancerConnector @ClevelandClinic, colleagues from @BrownMedicine, including Dr. Bene Carneiro @bcarneiro7, @SenduraiMani, @LiangChengMD, Matt Hadfield, Dr. @LiaTsimberidou from @MDAndersonNews, and Milan @carisls at 2025 WIN Symposium in Philly.
Dr. David Spetzler, President of @carisls speaks about DNA/RNA & TMB biomarkers, whole exomes, targeted fusions, AI opportunities & gives examples of predictions for patients with pancreatic cancer, lung cancer & breast cancer brain metastases, digital twins, & finding patterns.
October 4, 2025 at 4:02 AM
Dr. David Spetzler, President of @carisls speaks about DNA/RNA & TMB biomarkers, whole exomes, targeted fusions, AI opportunities & gives examples of predictions for patients with pancreatic cancer, lung cancer & breast cancer brain metastases, digital twins, & finding patterns.
Pleased to share collaborative manuscript by Totiger et al. with @carisls and Dr. Justin Taylor at @SylvesterCancer
(Nuclear Export Receptor) XPO1R749Q Mutations Co-occur with POLE Mutations in Cancer and can be Targeted to Overcome Chemoresistance
pubmed.ncbi.nlm.nih.gov/40531821/
(Nuclear Export Receptor) XPO1R749Q Mutations Co-occur with POLE Mutations in Cancer and can be Targeted to Overcome Chemoresistance
pubmed.ncbi.nlm.nih.gov/40531821/
XPO1R749Q Mutations Co-occur with POLE Mutations in Cancer and can be Targeted to Overcome Chemoresistance - PubMed
XPO1 is a nuclear export receptor that is essential for cell survival. Previous genomic analyses have identified recurrent XPO1 hotspot mutations in cancer. Here, we conducted a large-scale genomic an...
pubmed.ncbi.nlm.nih.gov
June 19, 2025 at 1:15 AM
Pleased to share collaborative manuscript by Totiger et al. with @carisls and Dr. Justin Taylor at @SylvesterCancer
(Nuclear Export Receptor) XPO1R749Q Mutations Co-occur with POLE Mutations in Cancer and can be Targeted to Overcome Chemoresistance
pubmed.ncbi.nlm.nih.gov/40531821/
(Nuclear Export Receptor) XPO1R749Q Mutations Co-occur with POLE Mutations in Cancer and can be Targeted to Overcome Chemoresistance
pubmed.ncbi.nlm.nih.gov/40531821/
TOP Biotechs at ASCO: David Spetzler on AI Signatures in NSCLC, Pancreatic Cancer, Recurrence
youtu.be/Y9xQFm1STHY
@carisls
youtu.be/Y9xQFm1STHY
@carisls
TOP Biotechs at ASCO: David Spetzler on AI Signatures in NSCLC, Pancreatic Cancer, Recurrence
YouTube video by OncoDaily TV
youtu.be
June 9, 2025 at 3:02 AM
TOP Biotechs at ASCO: David Spetzler on AI Signatures in NSCLC, Pancreatic Cancer, Recurrence
youtu.be/Y9xQFm1STHY
@carisls
youtu.be/Y9xQFm1STHY
@carisls
Sharing recent collaborative results through @carisls Precision Oncology Alliance👇
Molecular Characterization and Clinical Outcomes of Pancreatic Neuroendocrine Neoplasms Harboring PAK4-NAMPT Alterations
pubmed.ncbi.nlm.nih.gov/40330142/
Molecular Characterization and Clinical Outcomes of Pancreatic Neuroendocrine Neoplasms Harboring PAK4-NAMPT Alterations
pubmed.ncbi.nlm.nih.gov/40330142/
Molecular Characterization and Clinical Outcomes of Pancreatic Neuroendocrine Neoplasms Harboring PAK4-NAMPT Alterations - PubMed
Our study demonstrates that PAK4-high/NAMPT-high pNENs are associated with distinct molecular and immune profiles. Further investigation is warranted to determine if dual PAK4 and NAMPT blockade enhan...
pubmed.ncbi.nlm.nih.gov
May 7, 2025 at 2:33 PM
Sharing recent collaborative results through @carisls Precision Oncology Alliance👇
Molecular Characterization and Clinical Outcomes of Pancreatic Neuroendocrine Neoplasms Harboring PAK4-NAMPT Alterations
pubmed.ncbi.nlm.nih.gov/40330142/
Molecular Characterization and Clinical Outcomes of Pancreatic Neuroendocrine Neoplasms Harboring PAK4-NAMPT Alterations
pubmed.ncbi.nlm.nih.gov/40330142/
Sharing recent collaborative results through @carisls Precision Oncology Alliance👇
Multiomic Characterization of RCC1 and RCC2 Expression and Their Association With Molecular Alterations, Immune Phenotypes, and Cancer Outcomes
pubmed.ncbi.nlm.nih.gov/40330141/
Multiomic Characterization of RCC1 and RCC2 Expression and Their Association With Molecular Alterations, Immune Phenotypes, and Cancer Outcomes
pubmed.ncbi.nlm.nih.gov/40330141/
Multiomic Characterization of RCC1 and RCC2 Expression and Their Association With Molecular Alterations, Immune Phenotypes, and Cancer Outcomes - PubMed
<span><i>RCC1</i> and <i>RCC2</i> expression is a negative prognostic marker in NSCLC, PC, and CRC. Further studies to investigate <i>RCC1</i> and <i>RCC2</i> function at the molecular level may provi...
pubmed.ncbi.nlm.nih.gov
May 7, 2025 at 2:30 PM
Sharing recent collaborative results through @carisls Precision Oncology Alliance👇
Multiomic Characterization of RCC1 and RCC2 Expression and Their Association With Molecular Alterations, Immune Phenotypes, and Cancer Outcomes
pubmed.ncbi.nlm.nih.gov/40330141/
Multiomic Characterization of RCC1 and RCC2 Expression and Their Association With Molecular Alterations, Immune Phenotypes, and Cancer Outcomes
pubmed.ncbi.nlm.nih.gov/40330141/
Pleased to share this collaborative manuscript in @Cancer_Cell with @carisls
Mutation burden and anti-PD-1 outcomes are not universally associated with immune cell infiltration or lymphoid activation
www.sciencedirect.com/science/arti...
@BrownUCancer @BrownMedicine @BrownUniversity
Mutation burden and anti-PD-1 outcomes are not universally associated with immune cell infiltration or lymphoid activation
www.sciencedirect.com/science/arti...
@BrownUCancer @BrownMedicine @BrownUniversity
Mutation burden and anti-PD-1 outcomes are not universally associated with immune cell infiltration or lymphoid activation
www.sciencedirect.com
November 21, 2024 at 8:51 PM
Pleased to share this collaborative manuscript in @Cancer_Cell with @carisls
Mutation burden and anti-PD-1 outcomes are not universally associated with immune cell infiltration or lymphoid activation
www.sciencedirect.com/science/arti...
@BrownUCancer @BrownMedicine @BrownUniversity
Mutation burden and anti-PD-1 outcomes are not universally associated with immune cell infiltration or lymphoid activation
www.sciencedirect.com/science/arti...
@BrownUCancer @BrownMedicine @BrownUniversity